Cerebral amyloid angiopathy and its relationship to Alzheimer's disease
Thal DR, Griffin WS, de Vos RA, Ghebremedhin E.. Acta neuropathologica, 2008-03-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Cerebral amyloid angiopathy (CAA) is characterized by the deposition of the amyloid beta-protein (A beta) within cerebral vessels. The involvement of different brain areas in CAA follows a hierarchical sequence similar to that of Alzheimer-related senile plaques. Alzheimer's disease patients frequently exhibit CAA. The expansion of CAA in AD often shows the pattern of full-blown CAA. The deposition of A beta within capillaries distinguishes two types of CAA. One with capillary A beta-deposition is characterized by a strong association with the apolipoprotein E (APOE) epsilon 4 allele and by its frequent occurrence in Alzheimer's disease cases whereas the other one lacking capillary A beta-deposits is not associated with APOE epsilon 4. Capillary CAA can be seen in every stage of CAA or AD-related A beta-deposition. AD cases with capillary CAA show more widespread capillary A beta-deposition than non-demented cases as well as capillary occlusion. In a mouse model of CAA, capillary CAA was associated with capillary occlusion and cerebral blood flow disturbances. Thus, blood flow alterations with subsequent hypoperfusion induced by CAA-related capillary occlusion presumably point to a second mechanism in which A beta adversely affects the brain in AD in addition to its direct neurotoxic effects.
What this study adds
Evidence grade: Low
This is a narrative review. This paper describes how amyloid beta builds up in brain blood vessels (cerebral amyloid angiopathy), including a capillary form tied to the APOE epsilon 4 allele and often seen in Alzheimer's disease. In a mouse model, this capillary amyloid was linked to blocked capillaries and disturbed cerebral blood flow, suggesting a possible second way amyloid harms the brain beyond its direct toxic effects, but no treatment or prevention is tested here.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Thal, D. R., Griffin, W. S., de Vos, R. A., & Ghebremedhin, E. (2008). Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta neuropathologica. https://doi.org/10.1007/s00401-008-0366-2
Vancouver
Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta neuropathologica. 2008. doi:10.1007/s00401-008-0366-2. PMID: 18369648.
BibTeX
@article{thal2008-18369648,
author = {Thal, D. R. and Griffin, W. S. and de Vos, R. A. and Ghebremedhin, E.},
title = {{Cerebral amyloid angiopathy and its relationship to Alzheimer's disease}},
journal = {Acta neuropathologica},
year = {2008},
doi = {10.1007/s00401-008-0366-2},
pmid = {18369648},
url = {https://doi.org/10.1007/s00401-008-0366-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- One with capillary A beta-deposition is characterized by a strong association with the apolipoprotein E (APOE) epsilon 4 allele and by its frequent occurrence in Alzheimer's disease cases whereas the other one lacking capillary A beta-deposits is not associated with APOE epsilon 4.
- In a mouse model of CAA, capillary CAA was associated with capillary occlusion and cerebral blood flow disturbances.
Why it matters
This paper describes how amyloid beta builds up in brain blood vessels (cerebral amyloid angiopathy), including a capillary form tied to the APOE epsilon 4 allele and often seen in Alzheimer's disease. In a mouse model, this capillary amyloid was linked to blocked capillaries and disturbed cerebral blood flow, suggesting a possible second way amyloid harms the brain beyond its direct toxic effects, but no treatment or prevention is tested here.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 50/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Acta neuropathologica) |
| Journal's citation record | 3 / 4 | Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 373 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 18.6 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 4 / 6 | Cited 13.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 3 / 4 | Cited 69 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Estifanos Ghebremedhin: h-index 36 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Goethe University Frankfurt: institution h-index 958 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18369648) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also in Genetics
207 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.